Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rhodocollybia butyracea strain:CCBAS 279 | isolate:CCBAS 279

ABSTRACT: Rhodocollybia butyracea CCBAS 279 Standard Draft genome sequencing

PROVIDER: PRJNA500532 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8239480_subreads.fastq.gz	Fastqsanger.gz
	SRR8239477_subreads.fastq.gz	Fastqsanger.gz
	SRR8239478_subreads.fastq.gz	Fastqsanger.gz
	SRR8239479_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Rhodocollybia butyracea strain:CCBAS 279 | isolate:CCBAS 279

Project description:Rhodocollybia butyracea CCBAS 279 Transcriptome - RHO

| PRJNA537963 | ENA

Rhodocollybia butyracea

Project description:Rhodocollybia butyracea overview

| PRJNA373739 | ENA

Rhodocollybia butyracea strain:AH 40177

Project description:Rhodocollybia butyracea AH 40177 - Standard Draft genome sequencing

| PRJNA333300 | ENA

Rhodocollybia butyracea strain:AH 40177

Project description:Rhodocollybia butyracea AH 40177 - Transcriptome

| PRJNA372877 | ENA

Desarmillaria tabescens strain:CCBAS 213

Project description:Armillaria tabescens CCBAS 213 Standard Draft genome sequencing

| PRJNA519860 | ENA

Irpex lacteus strain:CCBAS Fr 238 617/93

Project description:Irpex lacteus CCBAS Fr. 238 617/93 Standard Draft genome sequencing

| PRJNA331356 | ENA

Bradyrhizobium diazoefficiens strain:USDA 279 | isolate:USDA 279

Project description:Bradyrhizobium diazoefficiens USDA 279 genome sequencing

| PRJNA1115699 | ENA

The ETS inhibitor YK-4-279 suppresses thyroid cancer progression independent of TERT promoter mutations

Project description:Hotspot mutations in the core promoter region of the telomerase reverse transcriptase (TERT) gene have been well established to associate with aggressive clinical characteristics, radioiodine refractory, tumor recurrence and mortality in thyroid cancer. Several E-twenty-six (ETS) transcription factors were reported to selectively bound to the mutant TERT promoter and activated TERT expression. In this study we aimed to investigate whether TERT promoter mutations confer sensitivity to ETS inhibitor YK-4-279 in thyroid cancer cells and whether this inhibitor could be served as a potential therapeutic agent for thyroid cancer. In vitro assays showed that YK-4-279 treatment sharply suppressed cell viability, colony formation, migration and invasion, as well as induced cell cycle arrest and apoptosis in a panel of thyroid cancer cells. The cell viability after YK-4-279 treatment were similar between cell lines harboring mutant and wild-type TERT promoter. Furthermore, YK-4-279 treatment reduced both luciferase activity and mRNA expression of TERT independent of TERT promoter mutation status. Data from RNA-seq further revealed that YK-4-279 significantly affected biological processes including DNA replication and cell cycle. Reduced DNA helicase activity and decreased expression of several helicase genes were observed after YK-4-279 treatment. Moreover, YK-4-279 significantly inhibited tumor growth and induced apoptosis in a xenograft mice model. Thus, ETS inhibitor YK-4-279 suppressed TERT expression and conferred anti-tumor activity in a TERT promoter mutation-independent manner, and it could be a potential agent for the treatment of advanced thyroid cancers.

2021-04-06 | GSE171473 | GEO

Panicum virgatum cultivar:SPR-279

Project description:Panicum virgatum exome capture - SPR-279

| PRJNA446191 | ENA

Azotobacter vinelandii strain:dsm 279

Project description:Azotobacter vinelandii DSM 279 Genome sequencing

| PRJNA296715 | ENA